Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simian virus 40 | 42 | 2019 | 137 | 10.560 |
Why?
|
| Polyomavirus Infections | 36 | 2019 | 139 | 7.330 |
Why?
|
| Tumor Virus Infections | 27 | 2016 | 224 | 5.010 |
Why?
|
| Polyomavirus | 8 | 2014 | 30 | 1.900 |
Why?
|
| JC Virus | 9 | 2014 | 43 | 1.770 |
Why?
|
| DNA, Viral | 21 | 2014 | 694 | 1.740 |
Why?
|
| BK Virus | 9 | 2014 | 123 | 1.510 |
Why?
|
| Antibodies, Viral | 13 | 2019 | 1320 | 1.500 |
Why?
|
| Antigens, Polyomavirus Transforming | 9 | 2018 | 110 | 1.240 |
Why?
|
| RNA, Viral | 3 | 2018 | 671 | 0.960 |
Why?
|
| Antibodies, Neutralizing | 3 | 2019 | 541 | 0.950 |
Why?
|
| Virus Shedding | 6 | 2014 | 88 | 0.890 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2007 | 1039 | 0.860 |
Why?
|
| Polymerase Chain Reaction | 16 | 2014 | 3203 | 0.790 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2019 | 7 | 0.700 |
Why?
|
| Drug Contamination | 6 | 2012 | 52 | 0.700 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2005 | 70 | 0.690 |
Why?
|
| Antigens, Viral, Tumor | 4 | 2016 | 47 | 0.660 |
Why?
|
| Lymphoma | 5 | 2009 | 1467 | 0.660 |
Why?
|
| Herpesvirus 4, Human | 5 | 2009 | 966 | 0.610 |
Why?
|
| Cell Transformation, Viral | 2 | 2018 | 138 | 0.600 |
Why?
|
| Viral Load | 7 | 2014 | 493 | 0.590 |
Why?
|
| HIV Infections | 7 | 2010 | 2134 | 0.580 |
Why?
|
| Poliovirus Vaccines | 4 | 2003 | 16 | 0.580 |
Why?
|
| Feces | 3 | 2014 | 770 | 0.570 |
Why?
|
| Genome, Viral | 4 | 2018 | 155 | 0.570 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2009 | 234 | 0.520 |
Why?
|
| Oncogenic Viruses | 2 | 2012 | 18 | 0.520 |
Why?
|
| Cricetinae | 6 | 2014 | 706 | 0.500 |
Why?
|
| MicroRNAs | 3 | 2018 | 2947 | 0.480 |
Why?
|
| Mesocricetus | 5 | 2014 | 114 | 0.460 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2003 | 317 | 0.440 |
Why?
|
| Lymphocytes | 1 | 2018 | 1234 | 0.440 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 222 | 0.430 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2009 | 489 | 0.430 |
Why?
|
| Genetic Variation | 3 | 2012 | 2086 | 0.430 |
Why?
|
| Neoplasms | 9 | 2012 | 15193 | 0.430 |
Why?
|
| Biodiversity | 1 | 2012 | 91 | 0.420 |
Why?
|
| Kidney Transplantation | 2 | 2012 | 755 | 0.420 |
Why?
|
| Seroepidemiologic Studies | 5 | 2019 | 129 | 0.410 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 1294 | 0.400 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2012 | 163 | 0.400 |
Why?
|
| Creatinine | 2 | 2012 | 531 | 0.380 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 1021 | 0.380 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2003 | 366 | 0.370 |
Why?
|
| Base Sequence | 11 | 2014 | 4917 | 0.350 |
Why?
|
| Space Flight | 3 | 2009 | 158 | 0.350 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2010 | 155 | 0.340 |
Why?
|
| Carrier State | 1 | 2009 | 90 | 0.340 |
Why?
|
| Haplorhini | 2 | 2008 | 130 | 0.340 |
Why?
|
| Molecular Sequence Data | 11 | 2016 | 6089 | 0.320 |
Why?
|
| HIV-1 | 4 | 2005 | 653 | 0.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 362 | 0.270 |
Why?
|
| Humans | 54 | 2019 | 261506 | 0.270 |
Why?
|
| Cell Line | 3 | 2018 | 5114 | 0.260 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2007 | 467 | 0.260 |
Why?
|
| Animals | 21 | 2016 | 59536 | 0.260 |
Why?
|
| Mesothelioma | 3 | 2007 | 544 | 0.250 |
Why?
|
| Medical Laboratory Personnel | 1 | 2004 | 21 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2004 | 29 | 0.240 |
Why?
|
| Gamma Rays | 1 | 2005 | 242 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 709 | 0.240 |
Why?
|
| Phylogeny | 2 | 2016 | 826 | 0.240 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1112 | 0.230 |
Why?
|
| Cells, Cultured | 6 | 2018 | 5637 | 0.230 |
Why?
|
| Lymph Nodes | 3 | 2010 | 2967 | 0.220 |
Why?
|
| Virion | 1 | 2003 | 161 | 0.220 |
Why?
|
| Pleural Neoplasms | 2 | 2007 | 470 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2003 | 297 | 0.210 |
Why?
|
| Genes, Regulator | 1 | 2002 | 69 | 0.210 |
Why?
|
| Adult | 21 | 2019 | 77950 | 0.210 |
Why?
|
| Macaca mulatta | 2 | 2014 | 717 | 0.200 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 110 | 0.200 |
Why?
|
| Virus Activation | 1 | 2003 | 228 | 0.200 |
Why?
|
| Texas | 6 | 2012 | 6311 | 0.200 |
Why?
|
| Female | 26 | 2019 | 141928 | 0.200 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 750 | 0.200 |
Why?
|
| Meningioma | 1 | 2004 | 289 | 0.190 |
Why?
|
| Male | 24 | 2019 | 123000 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 482 | 0.180 |
Why?
|
| Nicaragua | 1 | 2019 | 30 | 0.170 |
Why?
|
| Colombia | 1 | 2019 | 66 | 0.170 |
Why?
|
| Kidney Diseases | 3 | 2012 | 691 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2010 | 220 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 76 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 980 | 0.170 |
Why?
|
| Lung Transplantation | 3 | 2009 | 359 | 0.160 |
Why?
|
| Urine | 4 | 2010 | 143 | 0.160 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2018 | 18 | 0.160 |
Why?
|
| Adolescent | 9 | 2019 | 31252 | 0.160 |
Why?
|
| Middle Aged | 18 | 2016 | 86204 | 0.160 |
Why?
|
| Brain Neoplasms | 3 | 2004 | 4849 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 314 | 0.160 |
Why?
|
| Antibody Formation | 2 | 2009 | 383 | 0.150 |
Why?
|
| Incidence | 5 | 2007 | 5673 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2018 | 269 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2014 | 2483 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2009 | 4314 | 0.140 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2005 | 12 | 0.140 |
Why?
|
| Hodgkin Disease | 2 | 2005 | 1429 | 0.130 |
Why?
|
| Genes, Viral | 2 | 2005 | 202 | 0.130 |
Why?
|
| Logistic Models | 2 | 2012 | 3441 | 0.130 |
Why?
|
| Spleen | 2 | 2009 | 676 | 0.130 |
Why?
|
| Italy | 1 | 2014 | 236 | 0.120 |
Why?
|
| Prevalence | 3 | 2009 | 3260 | 0.120 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2014 | 187 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 1390 | 0.120 |
Why?
|
| DNA Primers | 3 | 2008 | 1399 | 0.120 |
Why?
|
| Sequence Alignment | 2 | 2005 | 844 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 9244 | 0.110 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 60 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2018 | 1385 | 0.110 |
Why?
|
| Vaccination | 1 | 2019 | 1123 | 0.110 |
Why?
|
| Virology | 2 | 2010 | 32 | 0.110 |
Why?
|
| Young Adult | 4 | 2019 | 21445 | 0.100 |
Why?
|
| Fetal Blood | 1 | 2014 | 482 | 0.100 |
Why?
|
| Models, Biological | 2 | 2012 | 3254 | 0.100 |
Why?
|
| Child | 6 | 2019 | 29154 | 0.100 |
Why?
|
| Cell Survival | 1 | 2018 | 3045 | 0.100 |
Why?
|
| Palatine Tonsil | 2 | 2008 | 53 | 0.100 |
Why?
|
| Nova Scotia | 1 | 2010 | 3 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2005 | 2314 | 0.090 |
Why?
|
| Mice | 3 | 2007 | 34495 | 0.090 |
Why?
|
| Virus Replication | 3 | 2014 | 709 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 1489 | 0.090 |
Why?
|
| Ribonuclease P | 1 | 2009 | 12 | 0.090 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 24 | 0.090 |
Why?
|
| Peptides | 1 | 2016 | 1479 | 0.090 |
Why?
|
| Viral Vaccines | 1 | 2012 | 304 | 0.090 |
Why?
|
| Bed Rest | 1 | 2009 | 23 | 0.090 |
Why?
|
| Bird Diseases | 1 | 2008 | 10 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2008 | 354 | 0.080 |
Why?
|
| Pregnancy | 2 | 2014 | 7573 | 0.080 |
Why?
|
| Virus Physiological Phenomena | 1 | 2008 | 19 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2004 | 1450 | 0.080 |
Why?
|
| Papio | 1 | 2008 | 70 | 0.080 |
Why?
|
| Birds | 1 | 2008 | 92 | 0.080 |
Why?
|
| Pharyngeal Diseases | 1 | 2008 | 53 | 0.080 |
Why?
|
| Cocarcinogenesis | 1 | 2007 | 50 | 0.080 |
Why?
|
| Asbestos | 1 | 2007 | 35 | 0.080 |
Why?
|
| Time Factors | 4 | 2009 | 12926 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 4971 | 0.070 |
Why?
|
| Antigens, Viral | 1 | 2008 | 471 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 2 | 2016 | 1487 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2016 | 4233 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2008 | 441 | 0.070 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 32 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2008 | 574 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 1375 | 0.070 |
Why?
|
| Oligonucleotide Probes | 1 | 2005 | 130 | 0.070 |
Why?
|
| Concanavalin A | 1 | 2005 | 67 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 7548 | 0.070 |
Why?
|
| Kazakhstan | 1 | 2005 | 4 | 0.070 |
Why?
|
| Kidney | 2 | 2012 | 2146 | 0.060 |
Why?
|
| Viral Plaque Assay | 1 | 2004 | 48 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7226 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 613 | 0.060 |
Why?
|
| Virus Latency | 1 | 2005 | 78 | 0.060 |
Why?
|
| Placenta | 1 | 2009 | 516 | 0.060 |
Why?
|
| Whole-Body Irradiation | 1 | 2005 | 307 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 1064 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2005 | 299 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 508 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 469 | 0.060 |
Why?
|
| Denmark | 1 | 2003 | 48 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2007 | 783 | 0.060 |
Why?
|
| Aged | 5 | 2016 | 70117 | 0.060 |
Why?
|
| Plasmids | 1 | 2005 | 837 | 0.060 |
Why?
|
| Species Specificity | 1 | 2004 | 777 | 0.060 |
Why?
|
| Risk Factors | 3 | 2012 | 17523 | 0.060 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2003 | 46 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 419 | 0.060 |
Why?
|
| Gadolinium | 1 | 2004 | 164 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2003 | 406 | 0.060 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 72 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 61 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2003 | 254 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2005 | 731 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2003 | 246 | 0.050 |
Why?
|
| Saliva | 1 | 2003 | 231 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 335 | 0.050 |
Why?
|
| Cytokines | 2 | 2009 | 2809 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 1945 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 997 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 29902 | 0.050 |
Why?
|
| Seasons | 1 | 2003 | 340 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1165 | 0.050 |
Why?
|
| Leucovorin | 1 | 2002 | 332 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 6009 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 144 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2005 | 1144 | 0.050 |
Why?
|
| Immune System | 1 | 2003 | 279 | 0.050 |
Why?
|
| Cell Division | 1 | 2005 | 2489 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2005 | 1681 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2008 | 16273 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 1682 | 0.050 |
Why?
|
| Bleomycin | 1 | 2002 | 467 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 2074 | 0.040 |
Why?
|
| Prednisone | 1 | 2002 | 984 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2005 | 6100 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 350 | 0.040 |
Why?
|
| Methotrexate | 1 | 2002 | 999 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 2359 | 0.040 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 698 | 0.040 |
Why?
|
| Mutation | 1 | 2018 | 15179 | 0.040 |
Why?
|
| Vincristine | 1 | 2002 | 1511 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2004 | 32848 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 15694 | 0.040 |
Why?
|
| Gene Expression | 1 | 2005 | 3570 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2002 | 1450 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2009 | 12873 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 13310 | 0.030 |
Why?
|
| Brain | 1 | 2009 | 4113 | 0.030 |
Why?
|
| Locus Control Region | 1 | 2014 | 15 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2016 | 185 | 0.030 |
Why?
|
| Genotype | 1 | 2003 | 4109 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 3001 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2002 | 3005 | 0.030 |
Why?
|
| Rabbits | 1 | 2016 | 957 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 218 | 0.030 |
Why?
|
| Age Factors | 1 | 2003 | 5377 | 0.030 |
Why?
|
| Genomics | 1 | 2004 | 2738 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 7222 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2006 | 5542 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2014 | 875 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3552 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 1732 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 2576 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 15862 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 2171 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2010 | 142 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 163 | 0.020 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 77 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 71 | 0.020 |
Why?
|
| Papio ursinus | 1 | 2008 | 1 | 0.020 |
Why?
|
| Papio cynocephalus | 1 | 2008 | 3 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 103 | 0.020 |
Why?
|
| Papio anubis | 1 | 2008 | 6 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 14551 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2008 | 75 | 0.020 |
Why?
|
| Animals, Laboratory | 1 | 2008 | 44 | 0.020 |
Why?
|
| Monkey Diseases | 1 | 2008 | 50 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2007 | 67 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 7702 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 10035 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 397 | 0.020 |
Why?
|
| Costa Rica | 1 | 2005 | 13 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2005 | 22 | 0.020 |
Why?
|
| United States | 1 | 2003 | 15433 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 1062 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2007 | 37905 | 0.020 |
Why?
|
| Germinal Center | 1 | 2005 | 161 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 2316 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2010 | 1818 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 132 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6207 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 2352 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 895 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 5047 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 1688 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6869 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 3443 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 14889 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 2278 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4557 | 0.010 |
Why?
|